Lantheus Holdings Inc, an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to Find, Fight and Follow serious medical conditions, announces that both the National Comprehensive Cancer Network (NCCN) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) have now updated their guidelines for the use of prostate specific membrane antigen (PSMA) positron emission tomography (PET) imaging.

Both the NCCN guidelines and the SNMMI appropriate use criteria note that all approved PSMA PET imaging agents, including PYLARIFY (piflufolastat F 18), may be used for patient selection for PSMA-targeted radioligand therapy.

“We are pleased that the NCCN and SNMMI have now both updated their guidelines to include PYLARIFY, the most widely adopted PSMA PET imaging agent, for patient selection for PSMA-targeted lutetium radioligand therapy,” said Bela Denes, MD, Lantheus Vice President of Medical Affairs. “We believe this will increase the accessibility to PSMA-targeted therapeutics for patients with advanced disease and further validates the benefit and utility that PYLARIFY provides to the U.S. prostate cancer community.”

Lantheus’ product, PYLARIFY, is a radioactive diagnostic agent indicated for PET imaging of PSMA positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and/or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. PYLARIFY was approved by the U.S. Food and Drug Administration in May 2021.

The NCCN is a not-for-profit alliance of 32 leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine.

The SNMMI is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 15,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field. The SNMMI Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process.

[Source(s): Lantheus Holdings Inc, GlobeNewswire]